These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 2494640)

  • 21. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
    Hodson ME; Gallagher CG; Govan JR
    Eur Respir J; 2002 Sep; 20(3):658-64. PubMed ID: 12358344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
    Wang X; Koehne-Voss S; Anumolu SS; Yu J
    J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
    Wiesemann HG; Steinkamp G; Ratjen F; Bauernfeind A; Przyklenk B; Döring G; von der Hardt H
    Pediatr Pulmonol; 1998 Feb; 25(2):88-92. PubMed ID: 9516091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
    Moss RB
    Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of inhaled tobramycin in cystic fibrosis.
    Shteinberg M; Elborn JS
    Adv Ther; 2015 Jan; 32(1):1-9. PubMed ID: 25620537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
    Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L
    Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial.
    Puvvadi R; Mikkelsen H; McCahon L; Grogan S; Ditcham W; Reid DW; Lamont I; Stick SM; Clements B
    J Cyst Fibros; 2021 Mar; 20(2):316-323. PubMed ID: 33341406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aerosol delivery of antibiotics to the lower airways of patients with cystic fibrosis.
    Fiel SB
    Chest; 1995 Feb; 107(2 Suppl):61S-64S. PubMed ID: 7842815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
    Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
    Antoniu S
    Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?
    Smith AL
    J Cyst Fibros; 2002 Dec; 1(Suppl 2):189-93. PubMed ID: 15463833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
    Konstan MW; Flume PA; Galeva I; Wan R; Debonnett LM; Maykut RJ; Angyalosi G
    Pediatr Pulmonol; 2016 Apr; 51(4):372-8. PubMed ID: 26709158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.
    Ratjen F; Brockhaus F; Angyalosi G
    J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.